RxDoctor Payments Data

Bilal Malik, MD

Interventional Cardiology · Brooklyn, NYNPI 1619926375

Payments from drug & device makers

$44,463in general payments, 2019–2025

Across 368 payments — averaging $120.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$37K
  • Medtronic$2K
  • Amgen$664
  • Pfizer$517
  • Abiomed$457
  • Novartis$450
  • plus $3K from 28 others

What the payments were for

  • Speaking & faculty fees$34,25077%
  • Food & beverage$10,18523%
  • Education$290%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,463 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$168,209
Medicare patients
734
Services billed
1,749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan263$250,195
FarxigaDapagliflozin Propanediol130$116,394
EliquisApixaban97$105,723
BrilintaTicagrelor89$60,631
JardianceEmpagliflozin28$24,843
DapagliflozinDapagliflozin Propanediol18$13,422
VascepaIcosapent Ethyl21$8,888
Repatha SyringeEvolocumab18$8,680
Metoprolol Succinate441$5,371
Ranolazine ErRanolazine74$5,250
Atorvastatin Calcium315$2,700
Ezetimibe140$2,537
Rosuvastatin Calcium125$1,819
ClopidogrelClopidogrel Bisulfate115$1,120
Losartan Potassium112$962

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$450$250,195263 claims
AstraZenecaFarxiga, Brilinta$359$177,025219 claims
PfizerEliquis$517$105,72397 claims
Boehringer IngelheimJardiance$84$24,84328 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →